财报显示，华泰柏瑞基金旗下华泰柏瑞中证光伏产业ETF进入上能电气前十大股东，且为今年一季度新进。今年以来收益率-5.43%，同类排名3398(总 3424)。 7月17日，上能电气连续5个交易日下跌，区间累计跌幅-5.40%。上能电气股份有限公司(股票代码:300827)是一家专注于电力电子产品研发、制造与销售的国 家高新技术企业,业务涵盖光伏逆变器、储能变流器及储能系统、电能质量治理、电站开发等多个领域,致力于提供全球领先的全场景"光储融合"解决方案,以 实力诠释"绿色、低碳、高效"的发展理念,引领行业创新,勇立时代潮头。 | ○ 基金经理 :李茜 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 累计任职时间:5年又256天 任职起始日期：2019-11-05 现任基金公司：华泰柏瑞基金管理有限公司 | | 基金经理简介：李茜女士:中国国籍,伦敦政治经济学院金融数学硕士。曾任职于上海市虹口区 金融服务局。2015年3月加入华泰柏瑞基金管理有限公司,历任指数投资部助理研究员、研究 员。2019年11月至2022年12月 ...

Core Viewpoint - The ETF performance in the first half of 2025 shows a stark contrast, with the Hong Kong innovative drug ETFs surging over 58%, while the photovoltaic industry ETFs faced a decline of over 11% [2][3]. Group 1: Performance of Innovative Drug ETFs - The top-performing ETFs are dominated by the pharmaceutical sector, particularly focusing on Hong Kong innovative drugs and biotechnology, indicating strong investor interest in the innovative drug field [3]. - The leading ETF, Huatai-PB Hong Kong Innovative Drug ETF, achieved a remarkable increase of 58.77%, with a scale of 7.802 billion [4]. - Other notable ETFs include Yinhua and Wanji's Hong Kong Innovative Drug ETFs, both exceeding 57% growth, showcasing significant capital involvement in the sector [4][5]. Group 2: Performance of Photovoltaic and Traditional Energy ETFs - In stark contrast, the coal and photovoltaic industry ETFs experienced significant declines, with the top loser, Guotai Zhongzheng Coal ETF, dropping by 12.28% [6][7]. - The photovoltaic ETFs collectively faced severe downturns, with all listed ETFs in this category recording declines exceeding 11%, reflecting the industry's adjustment pressures [7][8]. Group 3: Underlying Market Dynamics - The extreme market divergence reflects a sensitive response to changes in industry trends, driven by supportive policies for innovative drugs and the challenges faced by traditional energy and photovoltaic sectors [9]. - Recent policies from various government departments have provided robust support for the innovative drug industry, enhancing its development prospects [9][10]. - Conversely, the photovoltaic sector is grappling with overcapacity and financial losses, with expectations for a prolonged adjustment period before recovery [10]. Group 4: Future Outlook - The innovative drug market in China is projected to have significant growth potential, driven by low per capita medical spending and an aging population [11]. - The Hong Kong innovative drug sector is expected to continue its rapid development, supported by policy initiatives and advancements in research and commercialization [11][12]. - Long-term perspectives suggest that innovative drugs represent a "long slope, thick snow" sector, emphasizing the importance of distinguishing between thematic speculation and value growth [12].